SUSTAINED NANO SYSTEMS, LLC

small answers to big problems

SUSTAINED NANO SYSTEMS, LLC (SNS, the “Company”) is a privately held drug delivery technology company, incorporated in 2008.

The company utilizes its expertise in small particle behavior to produce nanovector and microvector components to enhance drug delivery. “Proof of concept” has been demonstrated in pre-clinical in-vitro and in-vivo studies.

The Company’s patented, polymer-based, drug delivery system utilizes drug-loaded nanoparticles and microparticles to deliver sustained and therapeutic levels of drugs to targeted tissues over periods of days, weeks, months or years, as required. The technology may be used to encapsulate a large array of drugs and offered through multiple modalities.

WHO WE ARE

Leadership

Barry Libin, DDS, MSD, MS

Dr. Libin is an experienced researcher and businessman in taking companies from inception through the development stages. He was Founder, Chairman and CEO of BML Pharmaceuticals Inc., a pharmaceutical research and development company in inflammatory and infectious diseases. Dr. Libin identified, formulated and directed clinical studies on a series of drugs having anti-inflammatory (Cox 2), anti-microbial and analgesic properties. BML’s lead drug in cancer therapy for prevention of chemotherapy and radiation induced mucositis was granted fast track status by the FDA and advanced through phase three clinical testing before BML was sold to Endo Pharmaceuticals in July of 2002. Following that Dr. Libin founded BML MedRecords Alert, LLC, an electronic medical records company that provides hospitals and physicians with “paperless” venues, and provides individual consumers with secure personal medical vaults. Dr. Libin received his DDS and his Masters (MSD) in Periodontics and Oral Medicine from NYU College of Dentistry, and his MS in Management and Policy from the Harriman School of Business at the State University at Stony Brook.

Jeffrey M. Liebmann, MD

Dr. Liebmann is Professor of Ophthalmology, Glaucoma Service Director, and Vice-Chair for the Department of Ophthalmology at Columbia University Medical Center. Dr. Liebmann graduated from Boston University’s Combined Six-Year Medical Education Program in 1983, completed his ophthalmology residency at the State University of New York/Downstate Medical Center, and glaucoma fellowship training at the New York Eye and Ear Infirmary. Dr. Liebmann was previously Clinical Professor of Ophthalmology at New York University School of Medicine and Director of Glaucoma Services at Manhattan Eye, Ear, and Throat Hospital and New York University Langone Medical Center. Dr. Liebmann is the immediate past-President of the World Glaucoma Association, past-President of the American Glaucoma Society, Secretary-Treasurer of the New York Glaucoma Society, and co-editor of Journal of Glaucoma and is a member of the Board of Governors of the World Glaucoma Association and Boards of Directors of The Glaucoma Foundation and the American Glaucoma Society Foundation. In addition to having one of the nation’s busiest tertiary-care glaucoma practices, Dr. Liebmann is also the Principal Investigator of the African Descent and Glaucoma Evaluation Study and is the author and/or co-author of more than 1,000 medical and scientific papers, book chapters, and abstracts. He has lectured widely in the United States and abroad on glaucoma diagnosis and management. His current main areas of research interest include the causes of glaucoma, glaucoma progression, glaucoma surgery, ocular imaging, and neuroprotection.

Weiliam Chen B.S., M.S., Ph.D.

Dr. Chen is a leading expert in biodegradable polymer matrices for drug and gene delivery and tissue engineering. Dr. Chen received his B.S. in Pharmacy from the University of Wisconsin, and his M.S. and Ph.D. from the University of Michigan in Pharmaceutics. Dr. Chen was Associate Professor of BioMedical Engineering in the Department of Surgery at New York University and past Associate Professor in the Department of Biomedical Engineering at the State University of New York at Stony Brook, where he jointly Co-founded EndoMedix, Inc., in the Long Island High Technology Incubator. Prior to that he was Manager of Drug/Gene Delivery Technologies at Clear Solutions (2001-2003). He has been awarded numerous grants from the NIH in the fields of biodegradable drug delivery devices and tissue engineering. He has written numerous peer reviewed articles and has lectured throughout the world.

David Beach, B.S., Ph.D.

Dr. Beach received his BS in Pharmacy at Union University-Albany College of Pharmacy and his Ph.D. at the University of Maryland. He is past President and COO of Synovics Pharmaceuticals where he was responsible for overall operations, including Prescription and Business Development. Previously he was Senior Consultant to VCG&A in Toronto where he managed the Phase II Clinical Program, and at Genpharm where he was Director of Research and Development. Dr. Beach was Associate Director of Pharmaceutical Process Improvement at Schering-Plough and Solids Development Senior Scientist/Group Leader at DuPont Pharmaceuticals.

Board of Directors

Robert I. Goldfarb, B.A., J.D.

Mr. Goldfarb, a member of the Board of Directors, has over twenty-five years of legal experience. Before joining SNS in December, 2011, Mr. Goldfarb was Senior Vice-President, General Counsel and Secretary of Andrx Corporation. Prior to that he was a partner with the law firm of Hughes, Hubbard and Reed. Mr. Goldfarb is presently President and General Counsel of Accu-Break Pharmaceuticals. He obtained his Bachelor’s degree from the University of Connecticut and his law degree from the University of Florida.

Adrienne L. Graves

Adrienne L. Graves, PhD, a member of the Board of Directors, is a visual scientist by training and a global industry leader in ophthalmology. From 2002 to 2010, Dr. Graves was President and Chief Executive Officer of Santen Inc., the US arm of Japan’s largest ophthalmic pharmaceutical company. She joined Santen in 1995 as VP of Clinical Affairs to initiate clinical development in the US, and was responsible for 3 NDA approvals. She was promoted to Sr. VP of Worldwide Clinical Affairs (Japan, US, and Europe), and was subsequently named a global Corporate Officer and CEO of US operations. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories, Inc., beginning in 1986 as a Senior Scientist. She progressed through various roles, including Director of International Ophthalmology.
Dr. Graves currently serves as an Independent Director on several corporate and foundation boards including the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, Pan-American Ophthalmology Foundation, and KeepYourSight Foundation; she also serves on the Corporation Committee for the Brown University Medical School and the Advisory Board for Amach Capital Partners. Dr. Graves cofounded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic Women Leaders (OWL). She received her AB in Psychology with honors from Brown University, her PhD in Psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Scientific Advisory Board

Robert I. Goldfarb, B.A., J.D.

Mr. Goldfarb, a member of the Board of Directors, has over twenty-five years of legal experience. Before joining SNS in December, 2011, Mr. Goldfarb was Senior Vice-President, General Counsel and Secretary of Andrx Corporation. Prior to that he was a partner with the law firm of Hughes, Hubbard and Reed. Mr. Goldfarb is presently President and General Counsel of Accu-Break Pharmaceuticals. He obtained his Bachelor’s degree from the University of Connecticut and his law degree from the University of Florida.

Please contact us for any inqueries you may have

©

Sustained Nano Systems, LLC. A New York LImited Liability Company